Primary peritoneal carcinoma

Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary peritoneal carcinoma, extra-ovarian serous carcinoma, primary serous papillary carcinoma, and psammomacarcinoma. It was historically classified under "carcinoma of unknown primary" (CUP). Primary peritoneal cancer (PPC, or PPCa)[1] is a cancer of the cells lining the peritoneum, or abdominal cavity.

Primary peritoneal carcinoma
Micrograph of a serous carcinoma, which may arise from the peritoneal lining
SpecialtyOncology 

Histomorphological and molecular biological characteristics suggest that serous carcinomas, which include ovarian serous carcinoma, uterine serous carcinoma, Fallopian tube serous carcinoma, cervical serous carcinoma, and primary peritoneal serous carcinoma really represent one entity.[2]

Genetic causes

Although the precise causes are not known, a link with certain variants of BRCA1/2 has been described.[3] Furthermore, women with BRCA1/2 mutation have a 5% risk of developing primary peritoneal cancer even after prophylactic oophorectomy.

Primary peritoneal carcinoma shows similar rates of tumor suppressor gene dysfunction (p53, BRCA, WT1) as ovarian cancer and can also show an increased expression of HER-2/neu.

An association with vascular endothelial growth factor has been observed.[4]

Prognosis

Prognosis and treatment is the same as for the most common type of ovarian cancer, which is epithelial ovarian cancer.[5][6]

The median survival of primary peritoneal carcinomas is usually shorter by 2–6 months time when compared with serous ovarian cancer. Studies show median survival varies between 11.3 and 17.8 months. One study reported 19–40 month median survival (95% CI) with a five-year survival of 26.5%.

Elevated albumin levels have been associated with a more favorable prognosis.[7]

References
  1. Jaaback KS, Ludeman L, Clayton NL, Hirschowitz L (2006). "Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period". Int. J. Gynecol. Cancer. 16 Suppl 1: 123–8. doi:10.1111/j.1525-1438.2006.00474.x. PMID 16515579. S2CID 2907689.
  2. Dubeau, L. (Dec 2008). "The cell of origin of ovarian epithelial tumours". Lancet Oncol. 9 (12): 1191–7. doi:10.1016/S1470-2045(08)70308-5. PMC 4176875. PMID 19038766.
  3. "Gynecologic Cancer Treatment—Primary Peritoneal Cancer—Dana-Farber Cancer Institute". Archived from the original on 2008-04-29. Retrieved 2008-05-07.
  4. Burger, Robert A.; Sill, Michael W.; Monk, Bradley J.; Greer, Benjamin E.; Sorosky, Joel I. (20 November 2007). "Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study". Journal of Clinical Oncology. 25 (33): 5165–5171. doi:10.1200/JCO.2007.11.5345. PMID 18024863.
  5. "New Drug Combination for Ovarian and Primary Peritoneal Cancers - National Cancer Institute". Archived from the original on 2010-12-24. Retrieved 2008-05-07.
  6. Peritoneal Cancer at eMedicine
  7. Alphs HH, Zahurak ML, Bristow RE, Díaz-Montes TP (December 2006). "Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer". Gynecol. Oncol. 103 (3): 1048–53. doi:10.1016/j.ygyno.2006.06.019. PMID 16876237.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.